The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.
Journal Article (Journal Article)
Cholesterol reduction from statin therapy has been one of the greatest public health successes in modern medicine. Simvastatin is among the most commonly used prescription medications. A non-synonymous coding single-nucleotide polymorphism (SNP), rs4149056, in SLCO1B1 markedly increases systemic exposure to simvastatin and the risk of muscle toxicity. This guideline explores the relationship between rs4149056 (c.521T>C, p.V174A) and clinical outcome for all statins. The strength of the evidence is high for myopathy with simvastatin. We limit our recommendations accordingly.
- Wilke, RA; Ramsey, LB; Johnson, SG; Maxwell, WD; McLeod, HL; Voora, D; Krauss, RM; Roden, DM; Feng, Q; Cooper-Dehoff, RM; Gong, L; Klein, TE; Wadelius, M; Niemi, M; Clinical Pharmacogenomics Implementation Consortium (CPIC),
- July 2012
Volume / Issue
- 92 / 1
Start / End Page
- 112 - 117
Pubmed Central ID
Electronic International Standard Serial Number (EISSN)
Digital Object Identifier (DOI)
- United States